Treatment of visceral leishmaniasis: a review of current treatment practices

Bibliography

• DESJEUX P: The increase in risk factors of leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. (2001) 95:239–243.
   PubMed Web of Science ®Google Scholar
• •Excellent update on the epidemiological problems of leishmaniasis worldwide.
   Google Scholar
• SEAMAN J, MERCER AJ, SANDORP E: The epidemic of visceral leishmaniasis of Upper Nile, Southern Sudan: course and impact from 1984 to 1994. Int. Epidemiol (1996) 25:862–871.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANISATION: Leishmania/HIV co-infection, South-western Europe 1990–1998. World Health Organization, Geneva, Switzerland. Mimeographed document (2000) WHO/LEISH/2000.42.
   Google Scholar
• WORLD HEALTH ORGANISATION:Report of the consultative meeting on Leishmania/HIV coinfection, Rome, 6–7 September, 1995. World Health Organization, Geneva, Switzerland. Mimeographed document (1995) WHO/LEISH/95.35/1995.
   Google Scholar
• ROSENTHAL E, MARTY P, POIZOT-MARTIN et al: Visceral leishmaniasis and HIV-1 co-infection in Southern France. Trans. R. Soc. Bop. Med. Hyg. (1995) 89:159–162.
   PubMed Web of Science ®Google Scholar
• WOLDAY D, BERHE N, AKUFFO H, BRITTON S: Leishmania/HIV interaction: immunopathogenic mechanisms. Parasitol Today (1999) 15:182–187.
   PubMedGoogle Scholar
• ROSENTHAL E, MARTY P, DEL GIUDICE P et al: HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin. Infect. Dis (2000) 31:1093–1095.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL E, TEMPESTA S, DEL GIUDICE P, MARTY P, PRADIER C, LE FICHOUX Y: Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy. AIDS (2001) 15:84–85.
   Google Scholar
• BRYCESON A: A policy for leishmaniasis with respect to the prevention and control of drug resistance. Bop. Med. Int. Health (2001) 6:928–993.
   PubMed Web of Science ®Google Scholar
• •Excellent reflection on this subject.
   Google Scholar
• HERWALDT BL, BERMAN JD: Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Bop. Med. Hyg. (1992) 46:296–306.
   PubMed Web of Science ®Google Scholar
• •Good review on the management of leishmaniasis with sodium stibogluconate.
   Google Scholar
• BERMAN JD: Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infec. Dis. (1988) 10:560–586.
   PubMedGoogle Scholar
• SUNDAR S, MORE DK, SINGH MK et al.: Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of indian epidemic. Clin. Infect. Dis. (2000) 31:1104–1106.
   PubMed Web of Science ®Google Scholar
• THAKUR CP: Sodium antimony gluconate, amphotericin, and myocardial damage. Lancet (1998) 351:1928–1929.
   PubMed Web of Science ®Google Scholar
• SANTOS J, RIVERO A, MARQUEZ M: Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection. Ann. Med. Intern. (2000) 7:562–563.
   Google Scholar
• VEEKEN H, RITMEIJER K, SEAMAN J, DAVIDSON R: Randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Bop. Med. Int. Health (2000) 5:312–317.
   PubMed Web of Science ®Google Scholar
• RITMEIJER K, VEEKEN H, MELAKU Y et al.: Ethiopian visceral leishmaniasis: generic and propriarity sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans. R. Soc. Med. Hyg. (2001) 95:668–672.
   PubMed Web of Science ®Google Scholar
• MOORE E, O'FLAHERTY D, HEUVELMANS H et al.: Comparison of generic and propiarity sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ. (2001) 79:388–393.
   Google Scholar
• SUNDAR S, SINHA PR, AGRAWAL NK et al: A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am. j Bop. Med. Hyg. (1998) 59:139–143.
   PubMed Web of Science ®Google Scholar
• FREZARD F, MICHALICK MS, SOARES CF, DEMICHELI C: Novel methods for the encapsulation of meglumine antimoniate into liposomes. Braz. .1. Med. Biol. Res. (2000) 33:841–846.
   PubMed Web of Science ®Google Scholar
• MISHRA M, BISWAS UK, JHA DN, KHAN AB: Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet (1992) 340:1256–1257.
   PubMed Web of Science ®Google Scholar
• THAKUR CP, SINGH RK, HASSAN SM, KUMAR R, NARAIN S, KUMAR A: Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans. R. Soc. Bop. Med. Hyg. (1999) 93:319–323.
   PubMed Web of Science ®Google Scholar
• SUNDAR S, GUPTA LB, RASTOGI V, AGRAWAL G, MURRAY HW: Short course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans. R. Soc. Bop. Med. Hyg. (2000) 94:200–204.
   PubMed Web of Science ®Google Scholar
• DAVIDSON RN, CROFT SL, SCOTT A, MAINI M, MOODY AH, BRYCESON ADM: Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet (1991) 337:1061–1062.
   PubMed Web of Science ®Google Scholar
• DAVIDSON RN, DI MARTINO L, GRAD ONI L et al.: Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (ambisome). Clin. Infect. Dis. (1996) 22:938–943.
   Google Scholar
• DIETZE R, FAGUNDES SMS, BRITO EF et al.: Treatment of kala azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans. R. Soc. Bop. Med. Hyg. (1995) 89:309–311.
   PubMedGoogle Scholar
• SUNDAR S, MURRAY HW: Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex (ABLC). Infect. Dis. (1996) 173:762–766.
   Google Scholar
• MURRAY HW: Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. (2001) 45:2185–2197.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on the treatment of VL. Numerous references, particularly on immunological aspects.
   Google Scholar
• SUNDAR S, AGRAWALL G, SINHA PR, HORWITH GS, MURRAY HW: Short course low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann. Intern. Med. (1997) 127:133–137.
   PubMed Web of Science ®Google Scholar
• THAKUR CP, PANDEY AK, SINHA GP, ROY S, BEHBEHANI K, OLLIARO P: Comparison of three treatment regimens with liposomal amphotericin B (ambisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans. R. Soc. Bop. Med. Hyg. (1996) 90:319–322.
   PubMed Web of Science ®Google Scholar
• GRADONI L: Chemotherapy of leishmaniasis and trypanosomiasis: advances and failures. Carr. Opin. Infect. Dis. (1996) 9:435–438.
   Google Scholar
• HERWALDT BL: Leishmaniasis. Lancet (1999) 354:1191–1199.
   PubMedGoogle Scholar
• •An extensive review on all clinical and therapeutic patterns of leishmaniases.
   Google Scholar
• RUSSO R, NIGRO LC, MINNITI Set al.: Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (Ambisome). Infect. (1996) 32:133–137.
   Google Scholar
• TORRE-CISNEROS J, VILLANUEVA JL, KINDELLAN JM, JURADO R, SANCHEZ-GUIJO P: Successful treatment of antimony resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin. Infect. Dis. (1993) 17:625–627.
   PubMed Web of Science ®Google Scholar
• BOLETIS JN, PEFANIS A, STATHAKIS C, HELIOTI H, KOSTAKIS A, GIAMARELLOU H: Visceral leishmaniases in renal transplant recipients: successful treatment with liposomal amphotericin B (Ambisome). Clin. Infect. Dis. (1999) 28:1308–1309.
   PubMedGoogle Scholar
• SUNDAR S, AGRAWALL G, RAT M, MAKHARIA MK, MURRAY HW: Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B randomized trial. Br. Med. J. (2001) 323:419–422.
   PubMed Web of Science ®Google Scholar
• •Interesting paper on the modern management of VL.
   Google Scholar
• DAS VN, RANJAN A, SINHA AN et al.: A randomized clinical trial of low dosage combination of pentamidine and allo-purinol in the treatment of antimony un-responsive cases of visceral leishmaniasis. .1 Assoc. Physicians India (2001) 49:609–613.
   Google Scholar
• SEAMAN J, PRYCE D, SONDORP H, WILKINSON R, BRYCESON ADM: Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. .1. Infect. Dis. (1994) 168:715–720.
   Google Scholar
• THAKUR CP, KANYOK TP, PANDEY AK et al.: A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans. R. Soc. Bop. Med. Hyg. (2000) 94:429–431.
   PubMed Web of Science ®Google Scholar
• THAKUR CP, KANYOK TP, PANDEY AK, SINHA GP MESSICK C, OLLIARO P: Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans. R. Soc. Bop. Med. Hyg. (2000) 94:432–433.
   PubMedGoogle Scholar
• KAGER PA, REES PH, WELLDE BT, HOCKMEYER WT, LYVERLY WH: Allopurinol in the treatment of visceral leishmaniasis. Trans. R. Soc. Bop. Med. Hyg. (1981) 75:556–559.
   PubMed Web of Science ®Google Scholar
• CHUNGE CN, GACHIHI G, MUIGAI R: Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans. R. Soc. Bop. Med. Hyg. (1985) 79:715–718.
   Google Scholar
• JHA TK: Evaluation of allopurinol in thetreatment of kala-azar occurring in North Bihar, India. Trans. R. Soc. Bop. Med. Hyg.(1983) 77:204–207.
   PubMed Web of Science ®Google Scholar
• RAGUSA R, DI CATALDO A, SAMPERI P, SCHILIRO G: Treatment of visceral leishmaniasis with meglumine and allopurinol. Am.' Dis. Child. (1993) 147:611–612.
   PubMedGoogle Scholar
• SINGH NK, JHA TK, SINGH IJ, JHA S:Combination therapy in Kala-azar.J. Assoc. Physicians India (1995) 43:319–320.
   PubMedGoogle Scholar
• DENEROLLE P, BOURDOISEAU G: Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). Vet. Intern. Med. (1999) 13:413–415.
   PubMedGoogle Scholar
• KOUTINAS AF, SARIDOMICHELAKIS MN, MYLONAKIS MEA et al: Randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vet. Parasitol (2001) 98:247–261.
   PubMed Web of Science ®Google Scholar
• CROFT SL, NEAL RA, PENDERGAST W, CHAN JH: The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani Biochem. Pharmacol (1987) 36:2633–2636.
   Google Scholar
• KUHLENCORD A, MANIERA T, EIBL H, UNGER C: Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother: (1992) 36:1630–1634.
   Google Scholar
• LE FICHOUX Y, ROUSSEAU D, FERRUA B et al.: Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in Balb/c mice. Antimicrob. Agents Chemother. (1998) 42:654–658.
   PubMed Web of Science ®Google Scholar
• CROFT SL, SNOWDON D, YARDLEY V: The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosome cruzi and Bypanosoma brucei Antimicrob. Chemother. (1996) 38:1041–1047.
   Google Scholar
• MURRAY HW, DELPH-ETIENNE S: Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. Infect. Dis. (2000) 181:795–799.
   Google Scholar
• URBINA JA: Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology (1997) 114(Suppl.):S91–S99.
   Google Scholar
• MURRAY HW, DELPH-ETIENNE S: Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. (2000) 68:288–293.
   PubMed Web of Science ®Google Scholar
• MURRAY HW: Suppression of posttreatment recurrence of experimental visceral leishmaniasis inT-cell-deficient mice by oral miltefosine. Antimicrob. Agents Chemother: (2000) 44:3235–3236.
   PubMed Web of Science ®Google Scholar
• SUNDAR S, ROSENKAIMER F, MAKHARIA MK, GOYAL AK, MANDAL AK, VOSS A et al.: Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 352:1821–1823.
   PubMed Web of Science ®Google Scholar
• SUNDAR S, GUPTA LB, MAKHARIA MK et al.: Oral treatment of visceral leishmaniasis with miltefosine. Ann. Bop. Med. Parasitol (1999) 93:589–597.
   PubMed Web of Science ®Google Scholar
• JHA TK, SUNDAR S, THAKUR TP: Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl. .1. Med. (1999) 341:1795–1800.
   Google Scholar
• •Excellent paper providing opening for future therapy of visceral leishmaniasis.
   Google Scholar
• SUNDAR S, MAKHARIA MK, MORE DK et al.: Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. (2000) 31:1110–1113.
   PubMed Web of Science ®Google Scholar
• BERMAN JD: Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. (1997) 24:684–703.
   PubMed Web of Science ®Google Scholar
• GANGNEUX JP: Données récentes sur le traitement de la leishmaniose viscérale. Presse Med. (1999) 28:2057–2066.
   PubMedGoogle Scholar
• MURRAY HW: Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int. I Infect. Dis. (2000) 4:158–177.
   PubMedGoogle Scholar
• SHERWOOD JA, GACHIHI GS, MUIGGAI RK et al.: Phase II efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin. Infect. Dis. (1994) 19:1034–1039.
   PubMed Web of Science ®Google Scholar
• DIETZE R, CARVALHO SF, VALLI LC et al.: Phase II trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi Am. j Trop. Med. Hyg. (2001) 65:685–689.
   Google Scholar
• MURRAY HW, GRANGER AM, MOHANTY SK: Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma and interleukin-2-independent. J. Infect. Dis. (1991) 163:622–624.
   PubMedGoogle Scholar
• SUNDAR S, MURRAY HW: Effect of treatment with interferon-gamma alone in visceral leishmaniasis. I Infect. Dis. (1995) 172:1627–1629.
   PubMed Web of Science ®Google Scholar
• BADARO R, FALCOFF E, BADARO FS et al.: Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl. Med. (1990) 322:16–21.
   PubMed Web of Science ®Google Scholar
• SUNDAR S, SINGH VP, SHARMA S, MAKHARIA MK, MURRAY HW: Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis. (1997) 176:1117–1119.
   PubMed Web of Science ®Google Scholar
• GRADONI L, BRYCESON A, DESJEUX P: Treatment of mediterranean visceral leishmaniasis. Bull. World Health Organ. (1995) 73:191–197.
   PubMed Web of Science ®Google Scholar
• Conclusions and recommendations of theIVth WHO joint meeting on Leishmania-HIV co-infections. Parasite (2001) 8:376–379.
   PubMedGoogle Scholar
• LAGUNA F, LOPEZ-VELEZ R, PULIDO F et al.: Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS (1999) 13:1063–1069.
   Google Scholar
• SORIANO V, DONA C, RODRIGUEZ-ROSADO R, BARREIRO P, GONZALEZ-LABOZ J: Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS (2000) 14:383–386.
   PubMed Web of Science ®Google Scholar
• BERENGUER J, COSIN J, MIRALLES P, LOPEZ JC, PADILLA B: Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS (2000) 14:2946–2948.
   PubMed Web of Science ®Google Scholar
• BERMAN JD, BADARO R, THAKUR CP et al.: Efficacy and safety of liposomal amphotericin B (Ambisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. (1998) 76:25–32.
   PubMed Web of Science ®Google Scholar
• SUNDAR S: Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health (2001) 6:849–854.
   PubMed Web of Science ®Google Scholar
• HARRAT Z, ADDADI K, BELKAID M, TABET-DERRAZ O: La leishmaniose viscérale en Algérie. Recensement des cas de leishmaniose viscérale. Buff Soc. Path. Ex. (1992) 85:296–301.
   PubMedGoogle Scholar
• MARTY P, LE FICHOUX Y, PRATLONG F, GARI-TOUSSAINT M: Human visceral leishmaniasis in Alpes-Maritimes, France: epidemiological characteristics for the period 1985-1992. Trans. R. Soc. Trop. Med. Hyg. (1994) 88:33–34.
   PubMed Web of Science ®Google Scholar
• ALVARJ, CANAVATE C, GUTIERREZ-SOLAR B et al.: Leishmania and human immunodeficiency virus coinfection: the first ten years. Clin. Microbial. Rev (1997) 10:298–319.
   PubMedGoogle Scholar
• •The key paper on LeishmanialHIV coinfection.
   Google Scholar
• KUBAR J, MARTY P, LELIEVRE A et al.:Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS(1998) 12:2147–2153.
   Google Scholar
• THAKUR CP: Epidemiological, clinical and therapeutic features of kala-azar (including post kala-azar dermal leishmaniasis). Trans. R. Soc. Trop. Med. Hyg (1984) 78:391–398.
   PubMed Web of Science ®Google Scholar